

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) ~~[[A]]~~ An isolated biopolymer marker ~~peptide~~ consisting of amino acid residues 2-12 of SEQ ID NO:1 ~~diagnostic for myocardial infarction (MI), intracerebral hemorrhage (ICH) or congestive heart failure (CHF).~~

Claims 2-35. (cancelled)

Claim 36. (currently amended) A method for diagnosing myocardial infarction (MI), intracerebral hemorrhage (ICH) or congestive heart failure (CHF) by determining the presence of a biopolymer marker consisting of amino acid residues 2-12 of SEQ ID NO:1 comprising:

~~(a) obtaining a sample from a patient,~~

~~[[b)]~~ (a) conducting mass spectrometric analysis on ~~[[said]]~~ a sample obtained from a patient in a manner effective to maximize ~~elucidation of discernible analysis of~~ peptide fragments contained therein; ~~[[and]]~~

~~(c) comparing mass spectrum profiles of a peptide consisting of amino acid residues 2-12 of SEQ ID NO:1 to mass spectrum profiles of peptides elucidated from said sample, wherein recognition of a mass spectrum profile in the sample displaying the characteristic profile of the mass spectrum profile for the peptide consisting of amino acid residues 2-12 of SEQ ID NO:1 is diagnostic for myocardial infarction (MI), intracerebral hemorrhage (ICH) or congestive heart failure (CHF)~~

(b) comparing a mass spectral profile of said biopolymer marker consisting of amino acid residues 2-12 of SEQ ID NO:1 to mass spectral profiles of peptides obtained and analyzed from said sample; and

(c) confirming the presence of said biopolymer marker consisting of amino acid residues 2-12 of SEQ ID NO:1 in said sample by identifying a mass spectral profile having an ion peak at about 1348 daltons; wherein the presence of said biopolymer marker consisting of amino acid residues 2-12 of SEQ ID NO:1 diagnoses myocardial infarction (MI), intracerebral hemorrhage (ICH) or congestive heart failure (CHF).

Claim 37. (currently amended) The method of claim 36, wherein [[the]] said sample is an unfractionated body fluid or a tissue sample.

Claim 38. (previously presented) The method of claim 36, wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

Claim 39. (previously presented) The method of claim 36, wherein said mass spectrometric analysis is Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS).

Claims 40. (previously presented) The method of claim 36, wherein said patient is a human.

Claim 41. (currently amended) A myocardial infarction (MI), intracerebral hemorrhage (ICH) or congestive heart failure (CHF) diagnostic kit comprising: (a) a peptide consisting of amino acid residues 2-12 of SEQ ID NO:1 and (b) an antibody that binds to said peptide in a sample obtained from a patient.

Claim 42. (currently amended) The myocardial infarction (MI), intracerebral hemorrhage (ICH) or congestive heart failure (CHF) diagnostic kit of claim 41, wherein said antibody is immobilized on a solid support.

Claim 43. (currently amended) The myocardial infarction (MI),
intracerebral hemorrhage (ICH) or congestive heart failure (CHF)
diagnostic kit of claim 41, wherein said antibody is labeled.